關鍵數據
0.200今開
0.216最高
5.02M成交量
虧損本益比TTM
--本益比動
--股利TTM
12.23%換手率
0.200昨收
0.195最低
761.90K成交額
虧損本益比靜
0.43市淨率
0.00%股息率 TTM
-35.35%ROA
1.32052週最高
1.38量比
-22.38M淨利潤
41.07M總股本
-0.6602每股盈餘TTM
4.17Beta
-92.33%ROE
0.24652週最低
10.54%振幅
5.76%毛利率
8.62M總市值
-2.26回報/風險
6.90%風險率
操作建議
Cosmos Health Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名112/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為。最高目標價為4.50。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Cosmos Health Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Cosmos Health Inc簡介
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
公司代碼COSM
公司Cosmos Health Inc
CEOSiokas (Grigorios)
網址https://www.cosmosholdingsinc.com/
公司股東
常見問題
Cosmos Health Inc(COSM)的當前股價是多少?
Cosmos Health Inc(COSM)的當前股價是 0.21。
Cosmos Health Inc 的股票代碼是什麼?
Cosmos Health Inc的股票代碼是COSM。
Cosmos Health Inc股票的52週最高點是多少?
Cosmos Health Inc股票的52週最高點是1.32。
Cosmos Health Inc股票的52週最低點是多少?
Cosmos Health Inc股票的52週最低點是0.25。
Cosmos Health Inc的市值是多少?
Cosmos Health Inc的市值是8.62M。
Cosmos Health Inc(COSM)股票的每股收益(EPS TTM)是多少
Cosmos Health Inc(COSM)股票的每股收益(EPS TTM)是-0.63。